Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Market Cap	$107.21M	P/E Ratio	N/A
52W High	$1.36	52W Low	$0.55
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-3.6%	52W Position	28.4%
Overall Score	38	Value Score	60
Quality Score	--	Technical Score	16

EPS Current Est	$-0.25	EPS Next Est	$-0.3
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATOS	$0.78	+3.75%	595.33K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATOS	$0.78	+3.8%	595.33K
3
4
5
6

ATOS

ATOS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Atossa Therapeutics Inc. Data in Excel

Get Atossa Therapeutics Inc. Data in Excel